A common mechanism for concurrent changes of diastolic muscle length and systolic function in intact hearts.
Mechanical properties of the myocardium at end diastole have been thought to be dominated by passive material properties rather than by active sarcomere cross-bridge interactions. This study tested the hypothesis that residual cross-bridges significantly contribute to end-diastolic mechanics in vivo and that changes in end-diastolic cross-bridge interaction parallel concurrent changes in systolic cross-bridge interaction. Open-chest anesthetized pigs were treated with intracoronary verapamil (n = 7) or 2,3-butanedione monoxime (BDM; n = 8). Regional left ventricular external work and end-diastolic pressure (EDP) versus end-diastolic segment length (EDL) relations were determined in the treated and untreated regions of each heart. Both agents reduced external work of treated regions to 31-38% of baseline and concurrently shifted EDP versus EDL relations to the right (i.e., greater EDL at a given EDP) by an average of 5% (P < 0.05). During washout of the drugs, EDP versus EDL returned to baseline in parallel with recovery of external work. Sarcomere length, measured by transmission electron microscopy in BDM-treated and untreated regions of the same hearts after diastolic arrest and perfusion fixation, was 8% greater in BDM-treated regions (P < 0.01). We concluded that residual diastolic cross-bridges significantly and reversibly influence end-diastolic mechanics in vivo. Alterations of end-diastolic and systolic cross-bridge interactions occur in parallel.
Lu
L
L
Cardiology Section, Department of Veterans Affairs Medical Center and University of Colorado Health Sciences Center, Denver, Colorado 80220, USA.
Xu
Y
Y
Zhu
P
P
Greyson
C
C
Schwartz
G G
GG
D000818:Animals; D003326:Coronary Circulation / Q000502:physiology; D003931:Diacetyl / Q000031:analogs & derivatives* / Q000494:pharmacology; D003971:Diastole / Q000187:drug effects / Q000502:physiology*; D006321:Heart / Q000187:drug effects / Q000502:physiology*; D006339:Heart Rate / Q000502:physiology; D006352:Heart Ventricles; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology*; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology*; D009206:Myocardium / Q000648:ultrastructure; D019188:Organ Preservation Solutions / Q000494:pharmacology; D013552:Swine; D013599:Systole / Q000187:drug effects / Q000502:physiology*; D016277:Ventricular Function, Left / Q000502:physiology; D014700:Verapamil / Q000494:pharmacology
D019188:Organ Preservation Solutions; C004717:diacetylmonoxime; D014700:Verapamil; D003931:Diacetyl